(Press-News.org) To fully optimize a drug therapy for osteoporosis and low bone mineral density (BMD), patients should maintain vitamin D levels above the limits recently recommended by the Institute of Medicine (IOM), according to a new study by researchers from Hospital for Special Surgery in New York. The study will be presented at the Endocrine Society's Annual Meeting in Boston, June 4-7.
The study demonstrated that maintaining a circulating vitamin D level above 33 ng/ml is associated with a seven-fold greater likelihood of having a more favorable outcome with bisphosphonate therapy. Last November, the IOM issued recommendations that 25-Hydroxy vitamin D levels of 20-30 ng/ml were adequate for normal, healthy people.
"You are seven times more likely to respond to bisphosphonates if your 25-Hydroxy vitamin D level is 33 ng/ml and above. If you want to see a particular outcome from this treatment, then maybe 20 to 30 is not appropriate," said Richard Bockman, M.D., Ph.D., chief of the Endocrine Service at Hospital for Special Surgery, who directed the study. "When you see a seven times greater effect, that is pretty impressive."
More than 20 million people take bisphosphonates to preserve and improve skeletal health, and reduce the risk of fractures that can be caused by low BMD and osteoporosis. These drugs, however, do not work well in some patients. Because vitamin D is important to bone health, the researchers investigated whether they could identify levels of vitamin D that are associated with improved outcomes in patients taking bisphosphonates.
They conducted a retrospective chart review of patients seen in an osteoporosis practice of Hospital for Special Surgery. They identified subjects who were female, postmenopausal, had been taking one of four FDA-approved bisphosphonate drugs for at least 18 months, and had undergone at least two BMD scans separated by 18 to 60 months. The four drugs are alendronate, residronate, ibandronate and zolendronate. Patients were not included if they were nonadherent to bisphosphonate therapy, were chronic steroid users, or had metabolic bone disease or chronic kidney disease.
The researchers collected data on age, body mass index, type of bisphosphonate taken, treatment duration, concurrent calcium supplementation, fracture prior to and during bisphosphonate therapy, BMD and T-score at four sites—lumbar spine, femoral neck, trochanter, and total hip—from the two most recent bone scans. "The way the data are expressed for a bone density is how many standard deviations are you away from the normal," explained Dr. Bockman. "One standard deviation from the normal is a T score of one. Two standard deviations is a T score of two. Below the normal, it is a minus two and above the normal is a plus two. If your bone density is more than 2.5 standard deviations below the normal, that defines a low bone mass that is considered to be osteoporosis." The researchers also collected data on circulating levels of vitamin D, obtained with and between the two most recent bone scans.
Patients were deemed nonresponders if they had more than a 3 percent decrease in BMD between the initial and follow-up bone scans, a low-trauma fracture or a T-score less than -3.0 despite at least 24 months of bisphosphonate therapy.
The study included 160 patients, of whom 89 were responders, and 71 were nonresponders, with 42 having decreased BMD, 17 sustaining a fracture, and 12 having a persistent low T-score. The investigators found that only 16.8 percent of responders whereas 54.9 percent of nonresponders had vitamin D levels less than 33 ng/ml. Patients with an average circulating vitamin D level of 33 ng/ml and above had a seven-fold greater likelihood of having a favorable response to bisphosphonates. "We selected 33 as the cutoff and subsequently showed that it was the right choice, with more being better," Dr. Bockman said. Nonresponse rates were higher in patients who had low levels of vitamin D: < 20 ng/ml (83.3%), 20-30 ng/ml (77.8%), 30-40 ng/ml (42.3%), and >40 ng/ml (24.6%).
"If you look at the medical literature, researchers talk perhaps about a 20 percent increase in response rate, occasionally a doubling, but when you see a sevenfold improvement in outcome, you have to be impressed that it is probably important," said Dr. Bockman, who is also professor of Medicine in the Endocrine Division of Weill Cornell Medical College.
Before this study, researchers had not formally studied the relationship between vitamin D levels and the effectiveness of bisphosphonates. "There has been a lot of controversy over the correct vitamin D level for people to have," Dr. Bockman said. "Vitamin D status should be optimized to improve outcomes in patients taking bisphosphonates."
Dr. Bockman pointed out that three associations—the American Geriatric Society, Endocrine Society, and the American College of Rheumatology—are coming out with or have guidelines that recommend vitamin D levels higher than the IOM recommended levels for healthy people.
###
Other investigators involved with the study include Albert Shieh, M.D., a third year medical resident, and Amanda Carmel, M.D., an instructor in Medicine, both at NewYork-Presbyterian Hospital/Weill Cornell Medical College. The study was supported by the Mary and David Hoar Fellowship of the New York Academy of Medicine to Dr. Amanda Carmel and by the National Institutes of Health funded Clinical and Translational Science Center of Weill Cornell Medical College and Hospital for Special Surgery.
About Hospital for Special Surgery
Founded in 1863, Hospital for Special Surgery (HSS) is a world leader in orthopedics, rheumatology and rehabilitation. HSS is nationally ranked No. 1 in orthopedics, No. 3 in rheumatology, No. 16 in neurology and No. 18 in geriatrics by U.S. News & World Report (2010-11), and has received Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center, and has one of the lowest infection rates in the country. From 2007 to 2011, HSS has been a recipient of the HealthGrades Joint Replacement Excellence Award. A member of the NewYork-Presbyterian Healthcare System and an affiliate of Weill Cornell Medical College, HSS provides orthopedic and rheumatologic patient care at NewYork-Presbyterian Hospital at New York Weill Cornell Medical Center. All Hospital for Special Surgery medical staff are on the faculty of Weill Cornell Medical College. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. Hospital for Special Surgery is located in New York City and online at http://www.hss.edu/.
For more information contact:
Phyllis Fisher
212-606-1197/646-584-2714
FisherP@hss.edu/ phyllis.fisher@gmail.com
Tracy Hickenbottom
212-606-1197
HickenbottomT@hss.edu
Study finds high levels of vitamin D needed for bone density drugs to work
2011-06-07
ELSE PRESS RELEASES FROM THIS DATE:
Not just skin and bones: Wrinkles could predict women's bone fracture risk
2011-06-07
Wrinkles are a telltale sign of aging, and they might also be able to predict a woman's bone fracture risk, according to Yale School of Medicine researchers who report in a new study that the severity and distribution of skin wrinkles and overall skin quality could tell the story of bone mineral density in early menopausal women.
The findings will be presented June 6 at the Endocrine Society Meeting in Boston, Mass., by Lubna Pal, associate professor in the Department of Obstetrics, Gynecology & Reproductive Science at Yale School of Medicine.
"Skin and bones share ...
Intravenous nutrition in critically ill patients should be delayed, study finds
2011-06-07
Patients in the intensive care unit who do not tolerate adequate nutrition from tube feeding should wait a week before receiving intravenous (IV) feeding because, compared with early IV feeding, it enhances recovery from critical illness. Results of a new multicenter study from Belgium will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.
"These findings have enormous impact for improving quality and reducing the cost of medical care for critically ill patients," said the study's principal investigator, Greet Van den Berghe, MD, PhD, a professor ...
Women's risk of heart disease after gestational diabetes differs by race
2011-06-07
New research finds that gestational diabetes, or pregnancy-related diabetes, may not raise the risk of heart disease independent of other cardiovascular risk factors except in certain high-risk populations, such as Hispanics. The results will be presented Monday at The Endocrine Society's 93rd Annual Meeting in Boston.
"The prevalence of gestational diabetes is increasing, and its impact for the mother can extend well beyond pregnancy by raising her risk of developing type 2 diabetes and heart disease," said study co-author Rhonda Bentley-Lewis, MD, of Massachusetts ...
Low vitamin D levels are related to decreased response to osteoporosis medicine
2011-06-07
Women with low bone density are seven times more likely to benefit from a bisphosphonate drug when their vitamin D blood levels are above recent recommendations from the Institute of Medicine (IOM) as adequate for bone health. These new study results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.
"Maintaining adequate vitamin D levels above those recently recommended by the IOM is important for optimizing a standard therapy for osteoporosis: bisphosphonates," said coauthor Richard Bockman, MD, PhD, chief of the endocrine service at ...
Desserts with a low glycemic index may benefit weight-loss efforts for obese children
2011-06-07
Overweight girls lose more weight and can better stay on a healthy diet if they eat sugar-free, low-fat desserts several times weekly, as opposed to any dessert once a week, a new study finds. The results will be reported Monday at The Endocrine Society's 93rd Annual Meeting in Boston.
"Dieters commonly splurge on dessert once a week, usually choosing fattening items," said lead investigator Antonia Dastamani, MD, PhD, a pediatrician and research fellow at Athens University School of Medicine in Athens, Greece. "However, we found a positive effect of more frequent consumption ...
Testosterone therapy improves memory in postmenopausal women
2011-06-07
Post-menopausal women have better memory after daily treatment with a testosterone spray for six months, a new preliminary study finds. The results will be presented Saturday at The Endocrine Society's 93rd Annual Meeting in Boston.
"Women have a higher risk of developing dementia compared to men," said Sonia Davison, MD, PhD, the study's lead investigator and a postdoctoral research fellow at Monash University, Melbourne. "These results offer a potential therapy, where none currently exists, to slow cognitive decline in women."
The researchers compared a control group ...
Father's Day 2011: Children's Book Author Dad, Grandfather Regales His Children and Grandchildren with 'Wanda and the Oblahlahs' Story, Lost in Attic for 35 Years
2011-06-07
This Father's Day, Joe Sutton's charming children's tale starring Wanda, a mischievous, gum-chewing yet lovable little girl, launches, giving a nod to the lost art of storytelling -- passing stories, family histories and values from one generation to the next. "Wanda and the Oblahlahs", (Bright Sky Press, September 2011), the brainchild of then Army Colonel Sutton, emerged at bedtime for his rambunctious young daughters, Gretchen and Megan. Now 35 years later, Wanda's imaginative adventure lives on for Sutton's grandchildren and, as a children's book, can share ...
Yearly zoledronic acid at lower-than-standard doses increases bone density
2011-06-07
A lower dose of zoledronic acid than currently recommended for prevention of bone fractures due to osteoporosis decreases bone resorption and increases bone density, and may be effective in reducing the risk of osteoporotic fractures, a study finds. The new research findings will be presented Monday at The Endocrine Society's 93rd Annual Meeting in Boston.
"Our research suggests that one fifth or one half of the recommended dose might be sufficient to decrease fracture risk," said Andrew Grey, MD, principal investigator of the study and an associate professor of medicine ...
Yo-yo dieting appears to be healthier than lifelong obesity
2011-06-07
A new study comparing lifelong obesity with the weight fluctuations of "yo-yo dieting" suggests it is better to attempt to lose weight despite repeated failures at keeping the weight off than to not diet and remain obese. The results will be presented Monday at The Endocrine Society's 93rd Annual Meeting in Boston.
"It is clear that remaining on a stable, healthy diet provides the best outcome for health and longevity," said the study's principal investigator, Edward List, PhD, a scientist at Ohio University, Athens. "However, obese individuals commonly weight cycle—they ...
High amounts of the hormone leptin are linked to decreased depression
2011-06-07
Women who have higher levels of the appetite-controlling hormone leptin have fewer symptoms of depression, and this apparent inverse relationship is not related to body mass index (BMI), a new study finds. On Monday the results will be presented at The Endocrine Society's 93rd Annual Meeting in Boston.
"Animal data suggest that leptin may reduce anxiety and improve depression. Our study in women suggests that leptin may indeed have antidepressant qualities," said the study's lead author, Elizabeth Lawson, MD, of Massachusetts General Hospital and Harvard Medical School ...